Publication Name	World Journal of Gastroenterology
Manuscript ID	9084
Country	Italy

Received	2014-01-20 08:39
Peer-Review Started	2014-01-20 10:59
To Make the First Decision	2014-02-14 17:23
Return for Revision	2014-02-18 21:34
Revised	2014-03-11 02:49
Second Decision	2014-04-09 09:26
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-04-09 11:09
Articles in Press	2014-05-23 10:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-06-16 16:41
Publish the Manuscript Online	2014-07-14 17:39

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy
Manuscript Source	Unsolicited Manuscript
All Author List	Michele Barone, Andrea Iannone and Alfredo Di Leo
Funding Agency and Grant Number
Corresponding Author	Michele Barone, MD, PhD, Professor of Medicine, Chief of Gastroenterology Unit, Department of Medical and Surgical Science, University of Foggia, Viale Pinto 1, 71122 Foggia, Italy. michele.barone@unifg.it
Key Words	Addition; HBeAg negative; HBsAg clearance; Nucleos(t)ide analogues; Peg-interferon
Core Tip	The ideal endpoint of antiviral therapy is HBsAg loss, a difficult goal to obtain, especially in HBeAg negative patients. A Caucasian 44-year-old male patient, HBeAg negative, genotype D, received lamivudine and, 4 years later, added adefovir because of a virological breakthrough. Five years later, considering his age, liver stiffness (4.3 kPa) and HBsAg levels (3533 IU/mL), we added Peg-interferon ?-2a for six months (3 in combination with nucleos(t)ide analogues followed by 3 of Peg-interferon monotherapy), obtaining a complete HBsAg clearance. This result has important clinical and pharmaco-economic implications, since nucleos(t)ide analogues therapy in HBeAg negative patients is considered a long-lasting/life-long treatment.
Publish Date	2014-07-14 17:39
Citation	Barone M, Iannone A, Di Leo A. HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogues therapy. World J Gastroenterol 2014; 20(26): 8722-8725
URL	http://www.wjgnet.com/1007-9327/full/v20/i26/8722.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i26.8722

Full Article (PDF)	WJG-20-8722.pdf
Full Article (Word)	WJG-20-8722.doc
Manuscript File	9084-Review.doc
Answering Reviewers	9084-Answering reviewers.pdf
Copyright License Agreement	9084-Copyright assignment.PDF
Non-Native Speakers of English Editing Certificate	9084-Language certificate.pdf
Peer-review Report	9084-Peer review.pdf
Scientific Editor Work List	9084-Scientific editor work list.doc